{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:35:01Z","timestamp":1789403701329,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"am","delay-in-days":345,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["NCM2020-08-01"],"award-info":[{"award-number":["NCM2020-08-01"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jconrel.2022.04.002","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T21:10:08Z","timestamp":1649193008000},"page":"880-891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Sorafenib-loaded silica-containing redox nanoparticles for oral anti-liver fibrosis therapy"],"prefix":"10.1016","volume":"345","author":[{"given":"Hao Thi","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long Binh","family":"Vong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Nagasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jconrel.2022.04.002_bb0005","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000456580","article-title":"Lessons from epidemiology: the burden of liver disease","volume":"35","author":"Rowe","year":"2017","journal-title":"Dig. Dis."},{"issue":"4","key":"10.1016\/j.jconrel.2022.04.002_bb0010","first-page":"787","article-title":"Diagnosis and epidemiology of cirrhosis","volume":"93","author":"Lefton","year":"2009","journal-title":"Med. Clin."},{"issue":"6","key":"10.1016\/j.jconrel.2022.04.002_bb0015","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2022.04.002_bb0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.mam.2007.09.002","article-title":"Myofibroblast\u2013like cells and liver fibrogenesis: emerging concepts in a rapidly moving scenario","volume":"29","author":"Parola","year":"2008","journal-title":"Mol. Asp. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2022.04.002_bb0025","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1053\/j.gastro.2008.07.065","article-title":"Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis","volume":"135","author":"Taura","year":"2008","journal-title":"Gastroenterology."},{"key":"10.1016\/j.jconrel.2022.04.002_bb0030","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","article-title":"Sorafenib (BAY 43-9006, Nexavar\u00ae), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature","volume":"407","author":"Adnane","year":"2006","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.jconrel.2022.04.002_bb0035","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.biopha.2017.01.107","article-title":"Sorafenib: a potential therapeutic drug for hepatic fibrosis and its outcomes","volume":"88","author":"Ma","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.jconrel.2022.04.002_bb0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jhep.2010.02.027","article-title":"New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis","volume":"53","author":"Wang","year":"2010","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.jconrel.2022.04.002_bb0045","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bcpt.12365","article-title":"The adverse effects of sorafenib in patients with advanced cancers","volume":"116","author":"Li","year":"2015","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.jconrel.2022.04.002_bb0050","doi-asserted-by":"crossref","first-page":"113902","DOI":"10.1016\/j.bcp.2020.113902","article-title":"Dose-dependent regulation of mitochondrial function and cell death pathway by sorafenib in liver cancer cells","volume":"176","author":"Rodr\u00edguez-Hern\u00e1ndez","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.04.002_bb0055","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.tox.2018.01.005","article-title":"Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells","volume":"395","author":"Paech","year":"2018","journal-title":"Toxicology."},{"issue":"2","key":"10.1016\/j.jconrel.2022.04.002_bb0060","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12094-014-1201-y","article-title":"Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis","volume":"17","author":"Ramirez-Labrada","year":"2015","journal-title":"Clin. Transl. Oncol."},{"issue":"10","key":"10.1016\/j.jconrel.2022.04.002_bb0065","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1158\/1535-7163.MCT-12-0093","article-title":"Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo","volume":"11","author":"Coriat","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.jconrel.2022.04.002_bb0070","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1021\/acs.chemrev.5b00346","article-title":"Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release","volume":"116","author":"Kamaly","year":"2016","journal-title":"Chem. Rev."},{"issue":"7","key":"10.1016\/j.jconrel.2022.04.002_bb0075","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1039\/c2cs15327k","article-title":"Design of polymeric nanoparticles for biomedical delivery applications","volume":"41","author":"Elsabahy","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2022.04.002_bb0080","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.addr.2012.09.022","article-title":"PEGylated nanoparticles for biological and pharmaceutical applications","volume":"64","author":"Otsuka","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.jconrel.2022.04.002_bb0085","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers","volume":"64","author":"Ensign","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.jconrel.2022.04.002_bb0090","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3109\/1061186X.2013.789033","article-title":"Nanocarriers for oral drug delivery","volume":"21","author":"Zhang","year":"2013","journal-title":"J. Drug Target."},{"issue":"6","key":"10.1016\/j.jconrel.2022.04.002_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11051-012-0920-7","article-title":"Colloidal stability of polymeric nanoparticles in biological fluids","volume":"14","author":"Lazzari","year":"2012","journal-title":"J. Nanopart. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2022.04.002_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11051-020-04785-y","article-title":"Effect of particle size and surface charge of nanoparticles in penetration through intestinal mucus barrier","volume":"22","author":"Bandi","year":"2020","journal-title":"J. Nanopart. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2022.04.002_bb0105","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijpharm.2017.08.118","article-title":"Modeling of the burst release from PLGA micro-and nanoparticles as function of physicochemical parameters and formulation characteristics","volume":"532","author":"de Azevedo","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"3\u20134","key":"10.1016\/j.jconrel.2022.04.002_bb0110","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ejps.2009.04.004","article-title":"Quantifying drug release from PLGA nanoparticulates","volume":"37","author":"Corrigan","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2022.04.002_bb0115","first-page":"42","article-title":"Towards controlled degradation of poly (lactic) acid in technical applications","volume":"7","author":"Teixeira","year":"2021","journal-title":"C"},{"issue":"7","key":"10.1016\/j.jconrel.2022.04.002_bb0120","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3109\/1061186X.2014.928716","article-title":"Silica-installed redox nanoparticles for novel oral nanotherapeutics\u2013improvement in intestinal delivery with anti-inflammatory effects","volume":"22","author":"Hossain","year":"2014","journal-title":"J. Drug Target."},{"issue":"20","key":"10.1016\/j.jconrel.2022.04.002_bb0125","doi-asserted-by":"crossref","first-page":"1700428","DOI":"10.1002\/adhm.201700428","article-title":"Newly designed silica-containing redox nanoparticles for oral delivery of novel TOP2 catalytic inhibitor for treating colon cancer","volume":"6","author":"Vong","year":"2017","journal-title":"Adv. Healthcare Mater."},{"issue":"2","key":"10.1016\/j.jconrel.2022.04.002_bb0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4155\/tde.11.153","article-title":"Nitroxide radicals and nanoparticles: a partnership for nanomedicine radical delivery","volume":"3","author":"Nagasaki","year":"2012","journal-title":"Ther. Deliv."},{"issue":"21","key":"10.1016\/j.jconrel.2022.04.002_bb0135","doi-asserted-by":"crossref","first-page":"17728","DOI":"10.1039\/C5RA25505H","article-title":"Stable and pH-responsive polyamidoamine based unimolecular micelles capped with a zwitterionic polymer shell for anticancer drug delivery","volume":"6","author":"Wang","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.jconrel.2022.04.002_bb0140","first-page":"305","article-title":"Preparation, in vitro and in vivo evaluation of polymeric nanoparticles based on hyaluronic acid-poly (butyl cyanoacrylate) and D-alpha-tocopheryl polyethylene glycol 1000 succinate for tumor-targeted delivery of morin hydrate","volume":"10","author":"Abbad","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.04.002_bb0145","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.2147\/IJN.S90347","article-title":"Positively charged micelles based on a triblock copolymer demonstrate enhanced corneal penetration","volume":"10","author":"Li","year":"2015","journal-title":"Int. J. Nanomedicine"},{"issue":"24","key":"10.1016\/j.jconrel.2022.04.002_bb0150","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1002\/adfm.201201316","article-title":"Multifunctional mesoporous silica nanoparticles for cancer-targeted and controlled drug delivery","volume":"22","author":"Zhang","year":"2012","journal-title":"Adv. Funct. Mater."},{"issue":"19","key":"10.1016\/j.jconrel.2022.04.002_bb0155","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1002\/adfm.201303533","article-title":"Cancer-targeted monodisperse mesoporous silica nanoparticles as carrier of ruthenium polypyridyl complexes to enhance theranostic effects","volume":"24","author":"He","year":"2014","journal-title":"Adv. Funct. Mater."},{"issue":"8","key":"10.1016\/j.jconrel.2022.04.002_bb0160","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/adhm.201300576","article-title":"Reactive oxygen species-scavenging nanomedicines for the treatment of oxidative stress injuries","volume":"3","author":"Yoshitomi","year":"2014","journal-title":"Adv. Healthcare Mater."},{"issue":"9","key":"10.1016\/j.jconrel.2022.04.002_bb0165","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/cells7090137","article-title":"Retinoids issued from hepatic stellate cell lipid droplet loss as potential signaling molecules orchestrating a multicellular liver injury response","volume":"7","author":"Bobowski-Gerard","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2022.04.002_bb0170","doi-asserted-by":"crossref","first-page":"557","DOI":"10.12659\/PJR.898936","article-title":"Organ atrophy induced by sorafenib and sunitinib\u2013quantitative computed tomography (CT) evaluation of the pancreas, thyroid gland and spleen","volume":"81","author":"Takahashi","year":"2016","journal-title":"Pol. J. Radiol."},{"issue":"3","key":"10.1016\/j.jconrel.2022.04.002_bb0240","article-title":"Small intestinal perforation caused by metastatic tumor necrosis after sorafenib (Nexavar\u00ae) therapy for advanced hepatocellular carcinoma","volume":"1","author":"Choi","year":"2012","journal-title":"Int. Cancer Conf. J."},{"issue":"1","key":"10.1016\/j.jconrel.2022.04.002_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7819-10-167","article-title":"Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma","volume":"10","author":"Inoue","year":"2012","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.jconrel.2022.04.002_bb0175","first-page":"185","article-title":"Postulated carbon tetrachloride mode of action: a review","volume":"25","author":"Manibusan","year":"2007","journal-title":"J. Environ. Sci. Health C Environ. Carc. Ecotoxicol. Rev."},{"issue":"11","key":"10.1016\/j.jconrel.2022.04.002_bb0180","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3390\/cells8111419","article-title":"TGF-\u03b2 in hepatic stellate cell activation and liver fibrogenesis\u2014updated 2019","volume":"8","author":"Dewidar","year":"2019","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.jconrel.2022.04.002_bb0250","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s002040050311","article-title":"Biochemical and morphological characterization of carbon tetrachloride-induced lung fibrosis in rats","volume":"70","author":"P\u00e4\u00e4kk\u00f6","year":"1996","journal-title":"Arch. Toxicol."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2022.04.002_bb0185","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijpharm.2014.02.047","article-title":"Galactosylated polymeric carriers for liver targeting of sorafenib","volume":"466","author":"Craparo","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.04.002_bib261","doi-asserted-by":"crossref","unstructured":"Y Li, J Wei, Y Wei, L Cheng, B Guo, F Meng, F Li, Z Zhong, Apolipoprotein E Peptide-Guided Disulfide-Cross-Linked Micelles for Targeted Delivery of sorafenib to Hepatocellular Carcinoma, Biomacromolecules. 21 (2) (2019 Dec 6) 716\u2013724.","DOI":"10.1021\/acs.biomac.9b01419"},{"issue":"1","key":"10.1016\/j.jconrel.2022.04.002_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1556-276X-7-91","article-title":"Antitumor activity of sorafenib-incorporated nanoparticles of dextran\/poly (dl-lactide-co-glycolide) block copolymer","volume":"7","author":"Kim","year":"2012","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.jconrel.2022.04.002_bb0200","doi-asserted-by":"crossref","first-page":"118782","DOI":"10.1016\/j.ijpharm.2019.118782","article-title":"Dual GSH-exhausting sorafenib loaded manganese-silica nanodrugs for inducing the ferroptosis of hepatocellular carcinoma cells","volume":"572","author":"Tang","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.jconrel.2022.04.002_bb0205","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.biotechadv.2015.01.003","article-title":"Polymeric micelles in mucosal drug delivery: challenges towards clinical translation","volume":"33","author":"Sosnik","year":"2015","journal-title":"Biotechnol. Adv."},{"issue":"7","key":"10.1016\/j.jconrel.2022.04.002_bb0210","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1039\/c0sm00999g","article-title":"Covalently cross-linked amphiphilic block copolymer micelles","volume":"7","author":"van Nostrum","year":"2011","journal-title":"Soft Matter"},{"issue":"1","key":"10.1016\/j.jconrel.2022.04.002_bb0215","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1517\/17425240903380446","article-title":"Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle\u2013cell interaction","volume":"7","author":"Kim","year":"2010","journal-title":"Exp. Opin. Drug Deliv."},{"issue":"2","key":"10.1016\/j.jconrel.2022.04.002_bb0220","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s11051-010-0085-1","article-title":"Stability of aqueous silica nanoparticle dispersions","volume":"13","author":"Metin","year":"2011","journal-title":"J. Nanopart. Res."},{"issue":"4","key":"10.1016\/j.jconrel.2022.04.002_bb0225","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1053\/j.gastro.2012.06.043","article-title":"An orally administered redox nanoparticle that accumulates in the colonic mucosa and reduces colitis in mice","volume":"143","author":"Vong","year":"2012","journal-title":"Gastroenterology."},{"issue":"33","key":"10.1016\/j.jconrel.2022.04.002_bb0235","doi-asserted-by":"crossref","first-page":"8393","DOI":"10.1016\/j.biomaterials.2013.06.032","article-title":"Suppression of NSAID-induced small intestinal inflammation by orally administered redox nanoparticles","volume":"34","author":"Sha","year":"2013","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2022.04.002_bb0255","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1146\/annurev-biochem-060815-014442","article-title":"Reactive oxygen species and neutrophil function","volume":"85","author":"Winterbourn","year":"2016","journal-title":"Annu. Rev. Biochem."},{"issue":"4","key":"10.1016\/j.jconrel.2022.04.002_bib262","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","article-title":"Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922001961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922001961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:35:56Z","timestamp":1759163756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922001961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":51,"alternative-id":["S0168365922001961"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.04.002","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sorafenib-loaded silica-containing redox nanoparticles for oral anti-liver fibrosis therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}